KR102470319B1 - 항균성 화합물 - Google Patents

항균성 화합물 Download PDF

Info

Publication number
KR102470319B1
KR102470319B1 KR1020207015574A KR20207015574A KR102470319B1 KR 102470319 B1 KR102470319 B1 KR 102470319B1 KR 1020207015574 A KR1020207015574 A KR 1020207015574A KR 20207015574 A KR20207015574 A KR 20207015574A KR 102470319 B1 KR102470319 B1 KR 102470319B1
Authority
KR
South Korea
Prior art keywords
alkyl
group
phenyl
cycloalkyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207015574A
Other languages
English (en)
Korean (ko)
Other versions
KR20200084875A (ko
Inventor
파울 메오
모하메드 나와즈 칸
세드릭 샤리에르
Original Assignee
디스쿠바 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102470319(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 디스쿠바 엘티디. filed Critical 디스쿠바 엘티디.
Publication of KR20200084875A publication Critical patent/KR20200084875A/ko
Application granted granted Critical
Publication of KR102470319B1 publication Critical patent/KR102470319B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Warehouses Or Storage Devices (AREA)
KR1020207015574A 2017-11-03 2018-11-02 항균성 화합물 Active KR102470319B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1718285.8 2017-11-03
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds
PCT/GB2018/053183 WO2019086890A1 (en) 2017-11-03 2018-11-02 Antibacterial compounds

Publications (2)

Publication Number Publication Date
KR20200084875A KR20200084875A (ko) 2020-07-13
KR102470319B1 true KR102470319B1 (ko) 2022-11-25

Family

ID=60664899

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015574A Active KR102470319B1 (ko) 2017-11-03 2018-11-02 항균성 화합물

Country Status (22)

Country Link
US (2) US11345694B2 (https=)
EP (2) EP4606375A3 (https=)
JP (2) JP7348897B2 (https=)
KR (1) KR102470319B1 (https=)
CN (1) CN111566099B (https=)
AU (1) AU2018361828B2 (https=)
BR (1) BR112020008531A2 (https=)
CA (1) CA3081423A1 (https=)
CL (2) CL2020001147A1 (https=)
CO (1) CO2020005420A2 (https=)
EA (1) EA202091118A1 (https=)
ES (1) ES3005164T3 (https=)
GB (1) GB201718285D0 (https=)
GE (2) GEAP202315801A (https=)
IL (1) IL274229B2 (https=)
MA (1) MA50504A (https=)
MX (2) MX2020004562A (https=)
PE (2) PE20221006A1 (https=)
SG (1) SG11202003717UA (https=)
UA (1) UA128475C2 (https=)
WO (1) WO2019086890A1 (https=)
ZA (1) ZA202002093B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
CN117545485A (zh) * 2021-05-03 2024-02-09 迪斯库瓦有限公司 抗菌化合物
AU2022270347B2 (en) * 2021-05-03 2025-09-25 Discuva Limited Antibacterial compound
US20250161980A1 (en) 2022-02-21 2025-05-22 Mitsui Chemicals, Inc. Metal member, metal-resin composite body, and method for producing metal member
CN118164937A (zh) * 2024-03-13 2024-06-11 北京联本医药化学技术有限公司 一种铵盐离子液体催化制备5-乙酰基-2,3-苯丙二氢呋喃的方法
CN120208965B (zh) * 2025-05-28 2025-08-12 四川大学 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物
CN121471219A (zh) * 2026-01-09 2026-02-06 四川大学 用于革兰氏阴性菌特异性抗菌治疗的咪唑-2-胺类衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
AU2003249977A1 (en) * 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
RU2367661C2 (ru) 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
WO2011080132A2 (en) 2009-12-17 2011-07-07 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
AU2012281281B2 (en) 2011-07-13 2017-06-01 Tiumbio Co., Ltd 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
CN113398271A (zh) * 2014-05-16 2021-09-17 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
EA037112B1 (ru) 2015-03-02 2021-02-08 Ригель Фармасьютикалс, Инк. Ингибиторы tgf-
WO2016141381A2 (en) 2015-03-05 2016-09-09 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fumihiko Akutsu 외, Polymer, Vol. 39(24), pp.6093-6098 (1998)*
Hans P. L. Steenackers 외, J. Med. Chem., Vol. 54, pp.472-484 (2011)*
Pyl Theodor 외, Chemische Berichte, Vol. 94(12), pp.3217-3223 (1961)*

Also Published As

Publication number Publication date
US20210163460A1 (en) 2021-06-03
US11345694B2 (en) 2022-05-31
EA202091118A1 (ru) 2020-08-06
IL274229B2 (en) 2023-05-01
JP2022025116A (ja) 2022-02-09
NZ764310A (en) 2023-04-28
CO2020005420A2 (es) 2020-07-31
MX2020004562A (es) 2020-08-13
CN111566099B (zh) 2023-06-02
IL274229A (en) 2020-06-30
PE20211390A1 (es) 2021-07-27
CN111566099A (zh) 2020-08-21
ZA202002093B (en) 2023-11-29
PE20221006A1 (es) 2022-06-15
EP3704105B9 (en) 2025-03-05
EP4606375A3 (en) 2025-11-19
IL274229B1 (en) 2023-01-01
BR112020008531A2 (pt) 2020-10-20
ES3005164T3 (en) 2025-03-14
WO2019086890A1 (en) 2019-05-09
CA3081423A1 (en) 2019-05-09
GEP20237522B (en) 2023-08-10
AU2018361828A1 (en) 2020-05-28
CL2021002263A1 (es) 2022-04-01
SG11202003717UA (en) 2020-05-28
JP2021501756A (ja) 2021-01-21
MA50504A (fr) 2020-09-09
AU2018361828B2 (en) 2023-05-18
CL2020001147A1 (es) 2020-08-14
EP4606375A2 (en) 2025-08-27
GEAP202315801A (en) 2023-03-27
EP3704105A1 (en) 2020-09-09
US20220372027A1 (en) 2022-11-24
EP3704105B1 (en) 2024-10-16
JP7348897B2 (ja) 2023-09-21
UA128475C2 (uk) 2024-07-24
ES3005164T9 (en) 2025-03-24
MX2021010246A (es) 2021-09-21
KR20200084875A (ko) 2020-07-13
GB201718285D0 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
KR102470319B1 (ko) 항균성 화합물
AU2021204116B2 (en) Colony stimulating factor-1 receptor (CSF-1R) inhibitors
KR102444482B1 (ko) 단백질 인산화효소 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물
KR101643435B1 (ko) 항세균성 화합물
CN108135887B (zh) 噁唑烷酮化合物及其作为抗菌剂的使用方法
JP2021523221A (ja) Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター
TW201002728A (en) Heterocyclic urea derivatives and methods of use thereof
JP4819980B2 (ja) 細菌性腸管疾患の治療のための５−ヒドロキシメチル−オキサゾリジン−２−オン誘導体
WO2011151619A1 (en) Compounds for the treatment of clostridium difficile associated disease
CN111527093B (zh) 抗菌杂环化合物及其合成
EA041456B1 (ru) Антибактериальные соединения
WO2016064982A1 (en) Nargenicin compounds and uses thereof as antibacterial agents
AU2017218556A1 (en) Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds
BR122023019818B1 (pt) Inibidores do receptor de fator-1 de estimulação de colônia (csf-1r), composição farmacêutica e seu uso

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200529

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200604

Comment text: Request for Examination of Application

PG1501 Laying open of application
AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220222

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220222

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220523

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201123

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20221005

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220916

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220615

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220523

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201123

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221121

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221122

End annual number: 3

Start annual number: 1

PG1601 Publication of registration